Jianming Xu, MD

Professor Jianming Xu, MD
 

Affiliated Hospital Cancer Center
Academy of Military Medical Sciences
Beijing, China

What kind of specific, actionable information is contained on a FoundationOne CGP report? Video

What kind of specific, actionable information is contained on a FoundationOne CGP report?

What kind of specific, actionable information is contained on a FoundationOne CGP report?
Professor Jianming Xu, MD

Professor Jianming Xu, MD

Can you discuss the information reported in the genomics alteration section of the FoundationOne Report, the targeted therapies that may be relevant, and the interpretive statement for each genomic alteration? Video

Can you discuss the information reported in the genomics alteration section of the FoundationOne Report, the targeted therapies that may be relevant, and the interpretive statement for each genomic alteration?

Can you discuss the critical information reported in the genomics alteration section of the FoundationOne Report, the targeted therapies that may be relevant, and the interpretive statement for each genomic alteration, and the biologic/therapeutic ...
Professor Jianming Xu, MD

Professor Jianming Xu, MD

What is the evidence that more personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient's disease are aligned with specific therapy, will improve patient outcomes? Video

What is the evidence that more personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient's disease are aligned with specific therapy, will improve patient outcomes?

What is the evidence that more personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient’s disease are aligned with specific therapy, will improve patient outcomes? To what extent are they improved with ...
Professor Jianming Xu, MD

Professor Jianming Xu, MD

In what kinds of non-melanoma cancers does BRAF V600 appear to be a targetable oncogene? What do initial studies using BRAF V600 to guide vemurafenib and cetuximab in patients with colorectal cancer show? Video

In what kinds of non-melanoma cancers does BRAF V600 appear to be a targetable oncogene? What do initial studies using BRAF V600 to guide vemurafenib and cetuximab in patients with colorectal cancer show?

In what kinds of non-melanoma cancers does BRAF V600 appear to be a targetable oncogene? What do initial studies using BRAF V600 to guide vemurafenib and cetuximab in patients with colorectal cancer show? Does your genomic profiling service ...
Professor Jianming Xu, MD

Professor Jianming Xu, MD